Prognostic impact of neoadjuvant therapy vs upfront surgery in patients with huge hepatocellular carcinoma undergoing curative resection

Table 5 Univariate and multivariate analyses of risk factors for overall survival

Variable	Univariate		Multivariate
	HR (95%CI)	P value	HR (95%CI)	P value
Treatment group (surgery vs NT)	2.334 (0.994-5.480)	0.052	2.860 (1.178-6.943)	0.020
Age (< 60 years vs ≥ 60 years)	0.794 (0.344-1.834)	0.589
Sex (male vs female)	0.946 (0.278-3.214)	0.929
Hypertension (absence vs presence)	1.334 (0.492-3.617)	0.571
Diabetes (absence vs presence)	2.466 (0.331-18.355)	0.378
ASA (I vs II)	1.002 (0.408-2.459)	0.997
Hepatitis B (absence vs presence)	0.258 (0.035-1.921)	0.186
Hepatitis C (absence vs presence)	21.789 (0.005-99916.054)	0.474
Hepatocirrhosis (absence vs presence)	0.392 (0.092-1.680)	0.207
Tumor number (multiple vs single)	1.823 (0.739-4.500)	0.193	1.866 (0.735-4.736)	0.190
Vascular invasion (absence vs presence)	0.910 (0.356-2.326)	0.843	0.828 (0.320-2.143)	0.697
PVTT		0.945
0 vs 3	1.002 (0.295-3.410)
1 vs 3	0.000 (0.000-)
2 vs 3	0.535 (0.055-5.159)
HVTT (absence vs presence)	0.713 (0.241-2.110)	0.541
BCLC stage		0.437
A vs C	0.836 (0.309-2.263)
B vs C	1.681 (0.509-5.558)
HBeAg (absence vs presence)	1.205 (0.356-4.074)	0.765
AFP group (< 400 ng/mL vs ≥ 400 ng/mL)	1.015 (0.434-2.376)	0.973
Anatomical resection (no vs yes)	0.991 (0.415-2.370)	0.984
Extensive liver resection (no vs yes)	0.600 (0.233-1.543)	0.289
Surgical method (scope vs octomy)	1.162 (0.451-2.992)	0.756
Adjuvant therapy (absence vs presence)	2.531 (1.081-5.926)	0.032	3.406 (1.400-8.284)	0.007

NT: Neoadjuvant therapy; ASA: American society of Aneshesiologists; PVTT: Portal vein tumor thrombosis; HVTT: Hepatic vein tumor thrombus; BCLC: Barcelona Clinic Liver Cancer; HBeAg: Hepatitis B e antigen; AFP: Alpha-fetoprotein.